News & Updates

Show Multimedia Only

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

13 Jul 2026

The use of leukotriene receptor antagonists (LTRAs), especially when combined with H1 antihistamines (H1AHs), can lower the risk of lung cancer in patients with asthma or allergic rhinitis, suggests a study.

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

13 Jul 2026

Gynaecologic cancers impact sexual health

13 Jul 2026 by

A study presented at ESMO Gynae 2026 underscores the prevalence of sexual health concerns among women with gynaecologic cancers receiving psycho-oncology care.

Gynaecologic cancers impact sexual health

13 Jul 2026

PSA screening in mainland China and HK highly cost-effective, may improve prostate cancer survival

12 Jul 2026 by

A microsimulation study conducted by researchers from the University of Hong Kong (HKU), Guangzhou Medical University, and Shanghai Jiao Tong University shows that prostate-specific antigen (PSA) screening would be highly cost-effective and significantly improve survival outcomes for patients with prostate cancer in China.

PSA screening in mainland China and HK highly cost-effective, may improve prostate cancer survival

12 Jul 2026

Novel cancer vaccine plus pembrolizumab prolongs PFS in advanced melanoma

11 Jul 2026 by

An investigational, immune-modulatory cancer vaccine, IO102-IO103, when combined with pembrolizumab results in sustained progression-free survival (PFS) compared with pembrolizumab alone in patients with advanced melanoma, reports a study.

Novel cancer vaccine plus pembrolizumab prolongs PFS in advanced melanoma

11 Jul 2026

Undernutrition may worsen survival outcomes in cancer patients

10 Jul 2026

Undernutrition appears to reduce overall survival (OS) in patients with cancer, suggests a recent study.

Undernutrition may worsen survival outcomes in cancer patients

10 Jul 2026

CheckMate 214: Nivolumab-ipilimumab remains standard of care as first-line treatment in aRCC

10 Jul 2026 by

Combination therapy with nivolumab and ipilimumab provides sustained survival benefit with durable responses compared with sunitinib for the first-line treatment of advanced renal cell carcinoma (aRCC), as shown by the phase III CheckMate 214 trial.

CheckMate 214: Nivolumab-ipilimumab remains standard of care as first-line treatment in aRCC

10 Jul 2026

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

10 Jul 2026 by

The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

10 Jul 2026

AI pathology model assists in liver cancer diagnosis

09 Jul 2026

A confidence-based artificial intelligence (AI) biomarker demonstrates clinical utility in the diagnosis of liver cancer, according to a real-world study.

AI pathology model assists in liver cancer diagnosis

09 Jul 2026

GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer

09 Jul 2026 by

Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.

GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer

09 Jul 2026

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

08 Jul 2026

Treatment with camrelizumab combined with apatinib demonstrates improvements in overall survival (OS), progression-free survival (PFS), and response rates in patients with esophageal squamous cell carcinoma (ESCC), a study has shown.

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

08 Jul 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

Gynaecologic cancers impact sexual health

Gynaecologic cancers impact sexual health

PSA screening in mainland China and HK highly cost-effective, may improve prostate cancer survival

PSA screening in mainland China and HK highly cost-effective, may improve prostate cancer survival

Novel cancer vaccine plus pembrolizumab prolongs PFS in advanced melanoma

Novel cancer vaccine plus pembrolizumab prolongs PFS in advanced melanoma

Undernutrition may worsen survival outcomes in cancer patients

Undernutrition may worsen survival outcomes in cancer patients

CheckMate 214: Nivolumab-ipilimumab remains standard of care as first-line treatment in aRCC

CheckMate 214: Nivolumab-ipilimumab remains standard of care as first-line treatment in aRCC

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

AI pathology model assists in liver cancer diagnosis

AI pathology model assists in liver cancer diagnosis

GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer

GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC